$2.08
23.51% yesterday
Nasdaq, May 20, 09:49 pm CET
ISIN
US7995661045
Symbol
SANA
Sector
Industry

Sana Biotechnology Inc Stock price

$2.09
+0.50 31.45% 1M
-0.44 17.39% 6M
+0.46 28.22% YTD
-6.54 75.78% 1Y
-2.39 53.35% 3Y
-33.01 94.05% 5Y
-33.01 94.05% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.41 24.40%
ISIN
US7995661045
Symbol
SANA
Sector
Industry

Key metrics

Market capitalization $471.41m
Enterprise Value $453.82m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.25
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-216.79m
Free Cash Flow (TTM) Free Cash Flow $-223.90m
Cash position $108.90m
EPS (TTM) EPS $-0.88
P/E forward negative
Short interest 70.44%
Show more

Is Sana Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Sana Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Sana Biotechnology Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Sana Biotechnology Inc forecast:

Buy
86%
Hold
14%

Financial data from Sana Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 17 17
27% 27%
-
-17 -17
27% 27%
-
- Selling and Administrative Expenses 38 38
7% 7%
-
- Research and Development Expense 144 144
41% 41%
-
-199 -199
35% 35%
-
- Depreciation and Amortization 17 17
27% 27%
-
EBIT (Operating Income) EBIT -217 -217
35% 35%
-
Net Profit -209 -209
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sana Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sana Biotechnology Inc Stock News

Neutral
Seeking Alpha
one day ago
Data from phase 1 studies using SC291 to treat patients with B-cell mediated autoimmune disorders and SC262 for patients with relapsed/refractory B-cell malignancies expected in 2025. First-in-human study using UP421 as a HIP-modified primary islet cell therapy to treat patients with Type 1 Diabetes established increase circulating C-peptide biomarker and without need of immunosuppressive thera...
Neutral
PRNewsWire
one day ago
NEW YORK , May 19, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
Business Wire
3 days ago
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 17, 2024. Sana is a biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-...
More Sana Biotechnology Inc News

Company Profile

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses in identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 13, 2018 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Harr
Employees 194
Founded 2018
Website www.sana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today